clinical trial

Showing 15 posts of 80 posts found.

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023
Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy

NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023
Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

September 13, 2023
Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

CymaBay shares results from phase 3 RESPONSE trial for seladelpar

September 8, 2023
Research and Development CymaBay, PBC, Pharmacy, clinical trial, seladelpar

CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023
Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …

BridgeBio Pharma shares positive feedback from FDA and EMA for phase 3 trial of infigratinib

September 7, 2023
Research and Development BridgeBio Pharma, EMA, FDA, Musculo-skeletal disorder, achondroplasia, clinical trial

BridgeBio Pharma has announced positive feedback from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on …

Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase

September 6, 2023
Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase

Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

September 5, 2023
Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …

First patient dosed in phase 1 study for chronic hepatitis B treatment

August 31, 2023
Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B

ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …

Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo

August 23, 2023
Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer

Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023
Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …

Recce Pharmaceuticals shares data from phase 1/2 trial for burn wound infection

August 21, 2023
Research and Development Recce Pharmaceuticals, Wound Healing, burn wounds, clinical trial, infection

Recce Pharmaceuticals has announced that it has completed its data analysis for its phase 1/2 clinical trial of Recce 327 …


Hutchmed announces phase 3 trial met primary endpoint for primary immune thrombocytopenia treatment

August 21, 2023
Research and Development HUTCHMED, Haematology, clinical trial, sovleplenib, thrombocytopenia

Hutchmed has announced that its phase 3 trial ESLIM-01 trial assessing the use of sovleplenib has met its primary endpoint …

Latest content